Table 3.
Adjusted comparison of clinically significant ADRs across treatment arms.
| Entire study |
Actionable patients |
|||||||
|---|---|---|---|---|---|---|---|---|
| Control N = 529a | PGx-guided N = 547a | OR (96% CI)b | p-valueb | Control N = 126a | PGx-guided N = 136a | OR (96% CI)b | p-valueb | |
| Clinically relevant ADRs | 81 (15%) | 68 (12%) | 0.79 (0.59, 1.13) | 0.2 | 24 (19.05%) | 14 (10.37%) | 0.48 (0.23, 0.98) | 0.049 |
| Age | 49 (40.58) | 49 (39.58) | 0.98 (0.97, 0.99) | 0.002 | 51 (44.58) | 50 (39.58) | 0.98 (0.95, 1.01) | 0.2 |
| Co-medications | 3.00 (2.00, 6.00) | 3.00 (2.00, 5.00) | 1.08 (1.02, 1.15) | 0.013 | 3.00 (1.00, 5.00) | 3.00 (2.00, 5.00) | 1.18 (1.05, 1.33) | 0.006 |
| Baseline QoL | 0.60 (0.40, 0.70) | 0.59 (0.40, 0.70) | 0.23 (0.10, 0.55) | 0.001 | 0.50 (0.40, 0.70) | 0.52 (0.40, 0.70) | ||
a
Median (IQR); n (%).
b
Logistic regression of any clinically relevant ADRs on treatment arm, age, concomitant medications, diagnosis and baseline QoL (entire study) or treatment arm, age and concomitant medications (actionable patients).